[Trial of device that is not approved or cleared by the U.S. FDA]

The aim of this Pilot Study is to demonstrate the safety and efficacy of the use of Tetranite-Stabilization Material (TN-SM) in delivering enhanced stability to immediately restored dental implants inserted into fresh extraction sockets, with both clinical and patient-related successful outcomes.

Study Overview

• Status: Withheld
• Conditions: Adhesive Dental
• Intervention / Treatment: Device: Tetranite Stabilization Material (TN-SM)

Detailed Description

The purpose of the present study is to evaluate the safety and efficacy of a single stage approach using Tetranite Stabilization Material (TN-SM). The purpose of the efficacy component of this study is a composite comprising: (1) First - To demonstrate and evaluate the ability of TN-SM to achieve immediate implant stabilization in sites otherwise unable to provide primary stability without requiring the delay in treatment imposed by the current multi-staged standard-of-care method; (2) Second - To demonstrate and evaluate the ability of TN-SM to achieve sufficient short-term stabilization of implants, as measured by resonance frequency analysis, as the device undergoes initial resorption and replacement with new bone; (3) Third - To demonstrate the ability of TN-SM to aid in the maintenance of alveolar bone, without buccal plate collapse and loss of crestal bone height; and Fourth (4) - To demonstrate and evaluate the ability of a TN-SM stabilized implant to achieve implant success (after criteria of Buser, et. al 1) after 12 months while the device undergoes significant resorption, facilitates osteoconduction, and replacement with new bone. In addition to the Primary Endpoints of establishing the Safety and Efficacy of Implant Stabilization and Implant Success throughout the initial 12 months of post-functional loading, the study also assesses several secondary endpoints over the course of the study and one-year follow-up, as outlined in the sections below. These include assessment of incidence, duration, and severity of adverse effects and events; assessment of increasing implant stiffness; assessment of bone levels, bone volumetric changes; patient satisfaction surveys, and assessment of periodontal and peri-implant health integral to implant success.

• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, W1G 7JD
    • Norton Implants

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Screening Inclusion Criteria

  • Subjects must have voluntarily signed the informed consent form before any study related procedures;
  • Subjects must be males or females who are a minimum of 20 years of age;
  • Subjects who require a single anterior maxillary tooth extraction and desire a replacement with a dental implant and immediate temporary crown. Candidate subjects may require more than one extraction, and all sites will be considered for inclusion in the study;
  • Subjects must have opposing dentition (natural teeth, fixed or removable restorations);
  • Subjects must be committed to the study and the required follow-up visits;
  • Subjects must be ASA I or ASA II;
  • Subjects who present with a sound bony housing with a visible buccal plate evident at the crest and fenestrations or dehiscences limited to <5.0mm diameter on a cone beam CT
  • • There must be sufficient bone height crestal to critical anatomical structures, i.e., the piriform foramen, and maxillary sinus, to safely place a dental implant within the bone contours. Extraction sockets should be able to accommodate an implant > 9.0mm in length;
  • Anatomical conditions must be present to allow an implant crown restoration to be placed at the candidate site, e.g., sufficient interocclusal space, incisal Class1 or Class 2 Div 1 relation, appropriate angulation of the ridge, etc.
  • Extraction Site Enrollment Inclusion Criteria
  • There is at least 2mm of apical bone below the apex of the extraction socket for positive seating of the implant;
  • Any implant site in which placement of the selected implant leaves an HDD > 2mm in the buccal direction between the implant surface and the labial plate at the most coronal aspect of the extraction socket.

• Extraction Site Enrollment Inclusion Criteria

  • There is at least 2mm of apical bone below the apex of the extraction socket for positive seating of the implant;
  • Any implant site in which placement of the selected implant leaves an HDD > 2mm in the buccal direction between the implant surface and the labial plate at the most coronal aspect of the extraction socket.

Exclusion Criteria:

• Screening Exclusion Criteria

  • Subjects with a systemic disease or condition affecting a major organ system that would preclude dental implant surgery (e.g., malignant neoplasm or chemotherapy in the past 6 months, uncontrolled diabetes, major infection, Cushing's syndrome, metabolic bone disease, immunosuppression, blood dyscrasias, healing bone fracture, myocardial infarction or cerebrovascular accident within the last six months, etc.);
  • Subjects with any contraindications for oral surgical procedures (e.g. scleroderma, etc.);
  • Subjects with mucosal diseases (e.g. erosive lichen planus, mucous membrane pemphigoid, erythema multiforme, etc.) in the localized area around the study implant site;
  • Subjects with bone diseases or conditions (e.g. Paget's disease, fibrous dysplasia, history of osteomyelitis, etc.) in the region of the potential study implant site;
  • Subjects with a history of local radiation therapy in the head/neck area or osteonecrosis of the jaws;
  • Subjects receiving, or having a recent or long-term history (> 5 years) of receiving, oral anti-osteoclastic agents [e.g., bisphosphonates, Fosamax® and Prolia® (denosumab); Forsteo® (teriparatide), strontium ranelate, etc.], or anti-angiogenesis factors;
  • Subjects receiving or having a recent history of receiving (within 1 year) intravenous anti-osteoclastic agents (e.g. Ibandronate, Boniva®; Zoledronate, Zometa®).
  • Subjects who have major active substance abuse problems (e.g., alcoholism, opiate addiction, methamphetamine abuse, etc.);
  • Subjects who are pregnant or intending to become pregnant during the duration of the study;
  • Subjects who are heavy smokers (defined as >10 cigarettes per day or >1 cigar per day or equivalent of electronic cigarette vaping) or chew tobacco;
  • Subjects with inadequate oral hygiene or who are unmotivated for adequate home care;
  • Subjects who have physical or mental handicaps that would interfere with the ability to perform adequate oral hygiene;
  • Subjects who have undergone administration of any investigational device within 30 days of enrollment in the study;
  • Subjects who are allergic or otherwise sensitive to any materials likely encountered during the course of the study (e.g. titanium, suture materials, local anesthetics);
  • Subjects with conditions or circumstances, which, in the opinion of the Investigator, would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability.

• Extraction Site Enrollment Exclusion Criteria

  • Any site into which the implant is not or cannot be placed during the same visit as the extraction
  • Any implant site where there is a dehiscence or fenestration of buccal or lingual plates of bone greater than 5mm in any direction;
  • Any implant site in which placement of the selected implant leaves an HDD greater than 5mm in any direction between the implant surface and the most coronal aspect of the osteotomy;
  • Any site which provides primary implant stability after seating as demonstrated by insertion torque of greater than or equal to 15Ncm;
  • Any implant site where, during the osteotomy preparation, a submarginal perforation develops

Study Plan

How is the study designed?

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tetranite Stabilized Dental Implants with Provisional Crown; Extraction of maxillary anterior teeth followed by immediate insertion and stabilization of dental implants with Tetranite in otherwise non-stable sites. A provisional crown will also be inserted during this surgery.	Device: Tetranite Stabilization Material (TN-SM); Dental adhesive for increased implant stabilization

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Implant Stabilization by Resonance Frequency Analysis	The primary endpoint is sufficient bone-to-implant interfacial stiffness post-placement of the implant stabilized by TN-SM, whereby, sufficient bone-to-implant interfacial stiffness is measured by Resonance Frequency Analysis (RFA) expressed as mean Implant Stability Quotient (ISQ, 0-100 scale, where higher is better) at 1-year post TN-SM device and implant placement. For the study to be considered successful, the lower bound of the one-sided 97.5% confidence interval for the mean ISQ should exceed the clinical threshold of 60.	12-month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Implant Stabilization by Resonance Frequency Analysis	Sufficient bone-to-implant interfacial stiffness measured by Resonance Frequency Analysis (RFA) expressed as Implant Stability Quotient (ISQ, 0-100 scale, where higher ISQ is better) at 15 minutes, 1 week, 1 month, 3 months, and 7 months post-implant placement. For each timepoint to be considered successful, the lower bound of the one-sided 97.5% confidence interval for the mean ISQ should exceed the clinical threshold of 60;	15 minutes, 3 months, and 7 months
Device Related Adverse Events	Low incidence, severity and duration of device-related adverse events throughout the 12-month post-implant placement follow-up period;	12-month
Implant Stabilization by Forward Torque Assessment	Immediate implant stabilization demonstrated by no rotation of the implant subjected to forward torque of 20 Ncm at 15 minutes after application of the TN-SM;	15 minutes
Implant Success (Composite Measure)	Composite measure of implant success throughout the 12-month post-loading follow-up period consisting of: Presence of the implant at its site of implantation; and,; Absence of a recurrent peri-implant infection with suppuration; and,; No perceptible mobility upon palpation;; Absence of encapsulation, defined as continuous radiolucency around the implant in a periapical radiograph;	12-month
Bone Level Maintenance	Crestal bone level maintenance assessed by analysis of two-dimensional periapical radiographic records showing no more than a 1.0mm loss of height throughout the 12-month post-loading follow-up period;	12-month
Volume Loss	Dimensional changes in bone volume will be evaluated: before tooth extraction, and through the 12-month post-loading follow-up period. CBCT data will be used to perform these assessments; Peri-implant tissue health demonstrated by direct measurement around the implant at 12 months after placement of the implant as compared to existing conditions in the oral cavity near adjacent teeth to the implant site and to baseline around the implant at 3 months post placement	12-month
Patient Satisfaction	Subject satisfaction using the VAS scale (0-100) for pain where 0 is no pain, esthetic outcome and function.	12-month

Collaborators and Investigators

• Sponsor: [Redacted]
• Collaborators: Dentsply Sirona Inc.
• Investigators: Study Chair: Grayson Allen, MBA, RevBio

Publications and helpful links

General Publications

• Cochran DL, Jones A, Sugita R, Brown MC, Guda T, Prasad H, Ong JL, Pollack A, Kay GW. Immediate Dental Implant Stabilization in a Canine Model Using a Novel Mineral-Organic Adhesive: 4-Month Results. Int J Oral Maxillofac Implants. 2020 Jan/Feb;35(1):39-51. doi: 10.11607/jomi.7891.

Study record dates

Study Major Dates

• Study Start: July 15, 2020
• Primary Completion: January 25, 2023
• Study Completion: January 25, 2023

Study Registration Dates

• First Submitted: July 17, 2020
• First Submitted That Met QC Criteria: July 17, 2020
• First Posted (Actual): July 21, 2020

Study Record Updates

• Last Update Posted (Actual): January 10, 2024
• Last Update Submitted That Met QC Criteria: January 7, 2024
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: dental implant; stabilization; resonance frequency analysis (RFA); bone adhesive; implant success; primary stability; ridge height
• Other Study ID Numbers: DVAL19033

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes